|
| Application potentials of hiPSC-derived cardiomyocytes in preclinical cardiotoxicity screening and post-marketing safety reevaluation of Chinese medicine |
| Hits 2287 Download times 1722 Received:November 03, 2016 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2017.02.03 |
| Key Words
hiPSC;cardiomyocyte;cardiotoxicity;high throughput screen;traditional Chinese medicine safety |
| Author Name | Affiliation | E-mail | | CHEN Xiao-nan | Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
Tianjin International Joint Academy of Biotechnology and Medicine, Research and Development Center of Traditional Chinese Medicine, Tianjin 300457, China | | | ZHU Yan | Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
Tianjin International Joint Academy of Biotechnology and Medicine, Research and Development Center of Traditional Chinese Medicine, Tianjin 300457, China | yanzhu.harvard@iCloud.com |
|
| Abstract
|
| Cardiotoxicity is one of the leading causes for drug failure. Compared with the western medicine, cardiotoxicity assessment of traditional Chinese medicine (TCM),which is composed of two or more ingredients, faces greater challenges. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) is equivalent to immature myocardial cells and can proliferate with impunity. It will bring revolutionary change to biomedicine. Based on database of PubMed and CNKI, this review aims to outline the recent progress made in high throughput screening assays for cardiotoxicity assessment and to discuss the potential applications of hiPSC-CM in innovative TCM drug discovery and safety reevaluation of TCM in market. |
|
|
|
|
|
|
|
